The FDA has issued updates on several drugs that are in shortage or have been discontinued:

• Aprepitant (Emend) Capsules (New – Discontinuation)
• Atropine Sulfate Injection (Updated – Currently in Shortage)
• Bupivacaine Hydrochloride and Epinephrine Injection, USP (Updated – Currently in Shortage) 
• Bupivacaine Hydrochloride Injection, USP (Updated – Currently in Shortage)
• Calcium Chloride Injection, USP (Updated – Currently in Shortage)
• Cefazolin Injection (Updated – Currently in Shortage)
• Carbidopa and Levodopa Extended Release Tablets (Updated – Currently in Shortage)
• Deferoxamine Mesylate for Injection, USP (Updated – Currently in Shortage)
• Dexrazoxane Injection (Updated – Currently in Shortage)
• Dextrose 50% Injection (Updated – Currently in Shortage)
• Diltiazem Hydrochloride (Updated – Currently in Shortage)
• Dobutamine Hydrochloride Injection (Updated – Currently in Shortage)
• Epinephrine Injection, Auto-Injector (New – Currently in Shortage)
• Epinephrine Injection, 0.1 mg/mL (Updated – Currently in Shortage)
• Fentanyl Citrate (Sublimaze) Injection (Updated – Currently in Shortage)
• Gabapentin Tablets (New – Discontinuation)   
• Heparin Sodium and Sodium Chloride 0.9% Injection (Updated – Currently in Shortage)
• Hydromorphone Hydrochloride Injection, USP (Updated – Currently in Shortage)
• Labetalol Hydrochloride Injection (Updated – Currently in Shortage)
• Lidocaine Hydrochloride (Xylocaine) Injection (Updated – Currently in Shortage)
• Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine (Updated – Currently in Shortage)
• Liotrix (Thyrolar) Tablets (New – Discontinuation)   
• Lorazepam Injection, USP (Updated – Currently in Shortage)
• Magnesium Sulfate Injection (Updated – Currently in Shortage)
• Methyldopa Tablets (Updated – Currently in Shortage)
• Metronidazole Injection, USP (Updated – Currently in Shortage)
• Morphine Sulfate Injection, USP (New – Currently in Shortage)   
• Multi-Vitamin Infusion (Adult and Pediatric) (Updated – Currently in Shortage)
• Normosol-M and 5% Dextrose Injection (New – Discontinuation)
• Penicillamine (Depen) Titratable Tablets (Updated – Currently in Shortage)
• Piperacillin and Tazobactam (Zosyn) Injection (Updated – Currently in Shortage)
• Polyethylene Glycol 3350 Powder, for Oral Solution (New – Discontinuation)   
• Potassium Chloride Injection (Updated – Currently in Shortage)
• Remifentanil (Ultiva) Lyophilized Powder for Solution Injection (Updated – Currently in Shortage)
• Sodium Bicarbonate Injection, USP (Updated – Currently in Shortage)
• Sodium Chloride 0.9% Injection Bags (Updated – Currently in Shortage)
• Sodium Chloride Injection USP, 0.9% Vials and Syringes (Updated – Currently in Shortage)
• Sterile Water (Updated – Currently in Shortage)
• Thioridazine Hydrochloride Tablets (Updated – Currently in Shortage)
• Thiothixene Capsules (Updated – Currently in Shortage)
• Trifluoperazine Hydrochloride Tablets (Updated – Currently in Shortage)
• Valsartan Tablets (Updated – Currently in Shortage)

According to the FDA:

“A drug receives Resolved status when the Drug Shortages Staff (DSS) determines that the market is covered, based on information from all manufacturers. The market is considered covered when supply is available from at least one manufacturer to cover total market demand. However, some manufacturers may not have all presentations available. DSS monitors the supply of products with Resolved status. For the most current supply information, contact the manufacturers.” 

(Source: U.S. Food & Drug Adminstration)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!